Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Posted by Geri Gentry on Oct 7th, 2026

Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $29.50.

A number of analysts have recently weighed in on ANL shares. Wall Street Zen upgraded Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday. Loop Capital set a $49.00 price objective on Adlai Nortye in a research report on Tuesday, September 8th. Jefferies Financial Group upgraded Adlai Nortye to a “strong-buy” rating in a research note on Monday. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Adlai Nortye in a research report on Tuesday, September 8th. Finally, Cantor Fitzgerald initiated coverage on Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating on the stock.

Check Out Our Latest Research Report on ANL

Insider Transactions at Adlai Nortye

In related news, CFO Xiaofeng Ye sold 5,667 shares of Adlai Nortye stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the sale, the chief financial officer directly owned 147,757 shares in the company, valued at $2,105,537.25. This trade represents a 3.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the business’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total transaction of $159,900.00. Following the transaction, the director directly owned 121,453 shares of the company’s stock, valued at $1,942,033.47. The trade was a 7.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 26,881 shares of company stock worth $411,060.

Hedge Funds Weigh In On Adlai Nortye

Hedge funds and other institutional investors have recently made changes to their positions in the business. SmartHarvest Portfolios LLC increased its position in Adlai Nortye by 8.5% in the 1st quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after acquiring an additional 1,279 shares during the period. Renaissance Technologies LLC acquired a new position in Adlai Nortye during the 1st quarter worth $457,000. Seven Fleet Capital Management LP bought a new position in shares of Adlai Nortye in the second quarter worth $1,302,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye in the first quarter worth $816,000. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Adlai Nortye during the first quarter valued at $1,140,000. 35.21% of the stock is currently owned by institutional investors and hedge funds.

Adlai Nortye Price Performance

Shares of NASDAQ ANL opened at $14.46 on Wednesday. The firm’s 50-day moving average price is $14.43 and its two-hundred day moving average price is $12.40. Adlai Nortye has a 52-week low of $0.88 and a 52-week high of $17.25.

About Adlai Nortye

(Get Free Report)

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.